KYVERNA THERAPEUTICS INC (KYTX) — insider trading
Health Care · NASDAQ
KYVERNA THERAPEUTICS INC (KYTX) has 17 reported SEC Form 4 insider transactions in our data (latest 2026-05-27).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-05-27 | Aktar Mert | Director | Grant / award / vesting (derivative) | 20,582 | $0.00 | $0 | Form 4 |
| 2026-05-27 | Aktar Mert | Director | Grant / award / vesting | 5,093 | $0.00 | $0 | Form 4 |
| 2026-05-27 | Shaw Christi | Director, Officer (Executive Chairperson) | Shares withheld for taxes / exercise cost | 4,194 | $8.59 | $36.0K | Form 4 |
| 2026-05-27 | SEIDENBERG BETH C | Director | Grant / award / vesting (derivative) | 20,582 | $0.00 | $0 | Form 4 |
| 2026-05-27 | SEIDENBERG BETH C | Director | Grant / award / vesting | 5,093 | $0.00 | $0 | Form 4 |
| 2026-05-27 | Cohen Fred E | Director | Grant / award / vesting (derivative) | 20,582 | $0.00 | $0 | Form 4 |
| 2026-05-27 | Cohen Fred E | Director | Grant / award / vesting | 5,093 | $0.00 | $0 | Form 4 |
| 2026-05-27 | CLARK IAN T | Director | Grant / award / vesting (derivative) | 20,582 | $0.00 | $0 | Form 4 |
| 2026-05-27 | CLARK IAN T | Director | Grant / award / vesting | 5,093 | $0.00 | $0 | Form 4 |
| 2026-05-18 | Martini Gregory S. | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 325,000 | $0.00 | $0 | Form 4 |
| 2026-05-04 | Dac Nadia | Officer (Chief Commercial Officer) | Grant / award / vesting (derivative) | 300,000 | $0.00 | $0 | Form 4 |
| 2026-03-13 | GEHCHAN NAJI | Officer (See Remarks) | Grant / award / vesting (derivative) | 105,000 | $0.00 | $0 | Form 4 |
| 2026-03-13 | GEHCHAN NAJI | Officer (See Remarks) | Grant / award / vesting | 18,000 | $0.00 | $0 | Form 4 |
| 2026-03-13 | Biddle Warner Weston | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 350,000 | $0.00 | $0 | Form 4 |
| 2026-03-13 | Biddle Warner Weston | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 58,000 | $0.00 | $0 | Form 4 |
| 2026-03-13 | GRASSO MARC | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 65,000 | $0.00 | $0 | Form 4 |
| 2026-03-13 | GRASSO MARC | Officer (Chief Financial Officer) | Grant / award / vesting | 10,000 | $0.00 | $0 | Form 4 |
Ask the chat about KYTX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: KYVERNA THERAPEUTICS INC (KYTX).
Last updated 2026-05-27 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.